ADMA: Future Stock Upside Will Rely On Plasma Margin Resilience

The analyst price target for ADMA Biologics has been revised slightly lower, with fair value moving from $18.33 to $17.60 as analysts factor in updated assumptions around revenue growth, profit margins, and a modestly higher future P/E multiple, while still citing the company’s profitable profile, growth potential, and exposure to supportive plasma-derived product dynamics.

Analyst Commentary

Recent Street research on ADMA Biologics reflects both confidence in the company’s fundamentals and some caution around risks and valuation, giving investors a mixed but useful reference point when thinking about the stock.

Bullish Takeaways

Bullish analysts point to ADMA Biologics as a profitable, high growth business, which they view as supportive of premium valuation multiples relative to less established plasma peers.
They highlight that ADMA’s plasma derived portfolio and U.S. based manufacturing and sales are insulated from Most Favored Nation policies, tariffs, and Medicare pricing negotiations, which they see as reducing policy related earnings risk.
Some bullish analysts frame the current targets, including a US$21 price objective, as reflecting confidence in the company’s ability to execute on its plasma collection and product distribution plans.
Supportive commentary often emphasizes that the current fair value revisions still rest on a profitable profile and ongoing growth potential in plasma derived products.

Bearish Takeaways

Bearish analysts have trimmed price targets by US$3 to US$6 in recent research, indicating a more cautious stance on how prior expectations align with current assumptions for ADMA Biologics.
Some of the more cautious commentary follows a short report, with concerns focused on what they describe as a lack of clarity, which they see as a risk factor for sentiment and valuation.
Target cuts suggest that certain analysts are reassessing the balance between ADMA’s growth profile and execution risks, leading them to adopt more conservative valuation frameworks.
These bearish views underscore that while the company is profitable, there is ongoing debate about the sustainability and magnitude of growth that should be embedded into forward P/E multiples.

What’s in the News for ADMA Biologics

ADMA Biologics is facing multiple securities fraud class action lawsuits alleging channel stuffing related to ASCENIV, undisclosed related party distribution agreements with Genesis BioPharma Services, and inadequate internal controls. These lawsuits follow a March 24, 2026 Culper Research report that was followed by an approximate 29% share price decline, with suits filed on behalf of investors who bought shares between August 9, 2024 and March 25, 2026. (Source: class action filings, Culper Research)
For Q1 2026, ADMA Biologics reported flat total revenue year over year, ASCENIV sales up about 28%, BIVIGAM revenue down 54% due to competitive and pricing pressures, gross margin at 71%, adjusted EBITDA up 24%, and adjusted net income up 22%. The company also updated 2026 revenue guidance to US$530 million to US$560 million and is using debt funding to accelerate share repurchases. (Source: Q1 2026 results)
ADMA Biologics withdrew its long term financial guidance in light of evolving market dynamics and IVIG market headwinds. Analysts responded by cutting price targets to around US$18 to US$20, and the stock experienced more than a 50% share price decline year to date alongside questions about revenue quality and corporate governance. (Source: earnings commentary, analyst reports)
The FDA approved an expanded label for ASCENIV to include pediatric patients aged two years and older with primary humoral immunodeficiency, following completion of a post marketing pediatric assessment. This allows ADMA Biologics to address a younger patient population than the prior indication for patients aged 12 and above. (Source: FDA approval announcement)
Raymond James initiated coverage on ADMA Biologics with an Outperform rating and a US$21 price target, highlighting the company’s profitability profile, focus on plasma derived products, and the role of ASCENIV. Other research points to mixed insider trading activity with both insider buying and net selling around the stock. (Source: Raymond James initiation report)

Valuation Changes for ADMA Biologics Stock

Fair Value: revised slightly lower from $18.33 to $17.60 per share.
Discount Rate: moved modestly higher from 7.27% to 7.28%.
Revenue Growth: trimmed from 20.80% to 16.88%, reflecting more conservative top line assumptions for ADMA Biologics.
Net Profit Margin: adjusted down from 42.45% to 40.58%.
Future P/E: raised from 12.57x to 13.95x, indicating a somewhat higher valuation multiple applied to ADMA Biologics earnings.

13 views

Key Takeaways

Adoption of manufacturing improvements, capacity expansions, and new products is driving margin growth, revenue diversification, and improved supply chain resilience.
Enhanced liquidity from refinancing and strong market demand underpins strategic growth initiatives and positions the company for sustained earnings improvement.
Heavy dependence on a limited product line, manufacturing and supply chain risks, and strong competition threaten future growth, profitability, and market share in a shifting healthcare landscape.

Catalysts

About ADMA Biologics

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.
Rapidly increasing adoption and utilization of ASCENIV, with a growing number of physicians and patient starts, is supported by aging populations and rising prevalence of immunodeficiency and infectious diseases-secular trends likely to drive ADMA's top-line revenue growth for years to come.
Expansion of plasma collection volumes and the acquisition of new facilities are set to increase production capacity and supply chain resilience, positioning ADMA to capture greater market share and further accelerate revenue growth and earnings over the long term.
The recent debt refinancing, lowering the cost of capital and providing a new $300 million credit facility, enhances liquidity and financial flexibility, supporting ongoing strategic growth initiatives and potentially improving future free cash flow and EPS.
Continued progress in the product pipeline-including SG-001, which addresses unmet infectious disease needs and could potentially add $300–$500 million in annual revenue-offers significant future earnings upside and diversification of revenue streams.

ADMA Biologics Earnings and Revenue Growth

ADMA Biologics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming ADMA Biologics's revenue will grow by 16.9% annually over the next 3 years.
Analysts assume that profit margins will increase from 32.4% today to 40.6% in 3 years time.
Analysts expect earnings to reach $330.4 million (and earnings per share of $1.36) by about June 2029, up from $165.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $400.8 million in earnings, and the most bearish expecting $274.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 14.0x on those 2029 earnings, up from 12.0x today. This future PE is lower than the current PE for the US Biotechs industry at 16.4x.
Analysts expect the number of shares outstanding to decline by 2.87% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.28%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

ADMA's heavy reliance on a narrow product portfolio-primarily ASCENIV® and BIVIGAM®-leaves the company vulnerable to product-specific competition, potential regulatory setbacks, or clinical disappointments, which could materially impact future revenue growth and earnings stability.
The anticipated long-term margin expansion and revenue acceleration is highly dependent on the successful commercial scale-up and sustained efficiency of the proprietary yield enhancement manufacturing process; unforeseen scale-up challenges, regulatory delays, or operational disruptions at the Boca Raton facility could undermine projected cost reductions and gross margin improvements, resulting in weaker-than-expected profitability.
Persistent operating risks associated with plasma collection-such as potential supply constraints from donor fatigue, changes in donor demographics, or tighter industry regulations-may drive up raw material costs and disrupt supply chain continuity, posing a threat to cost of goods sold and net margin performance.
Increasing competition from larger, better-capitalized plasma industry leaders (e.g., CSL, Takeda, Grifols) with broader distribution networks and R&D resources may limit ADMA's ability to maintain high revenue growth rates and exert pricing power, potentially eroding future market share and constraining revenue expansion.
Secular healthcare trends-such as global cost containment, downward pressure on reimbursement rates, and advances in synthetic/alternative immunology therapies-could eventually reduce demand for plasma-derived products and compress pricing, negatively impacting long-term top-line growth and reducing the company's ability to sustain margin expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $17.6 for ADMA Biologics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $21.0, and the most bearish reporting a price target of just $12.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $814.2 million, earnings will come to $330.4 million, and it would be trading on a PE ratio of 14.0x, assuming you use a discount rate of 7.3%.
Given the current share price of $8.58, the analyst price target of $17.6 is 51.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ADMA Biologics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Share Repurchase And Higher Margins Will Drive Future Upside Potential